- Home
- DSGN vs CDXS Comparison
DSGN vs CDXS Comparison
Compare DSGN & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- CDXS
- Stock Information
- Founded
- DSGN 2017
- CDXS 2002
- Country
- DSGN United States
- CDXS United States
- Employees
- DSGN N/A
- CDXS N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- CDXS Major Chemicals
- Sector
- DSGN Health Care
- CDXS Industrials
- Exchange
- DSGN Nasdaq
- CDXS Nasdaq
- Market Cap
- DSGN 224.8M
- CDXS 201.3M
- IPO Year
- DSGN 2021
- CDXS 2010
- Fundamental
- Price
- DSGN $3.91
- CDXS $2.30
- Analyst Decision
- DSGN Hold
- CDXS Buy
- Analyst Count
- DSGN 1
- CDXS 2
- Target Price
- DSGN $4.00
- CDXS $11.00
- AVG Volume (30 Days)
- DSGN 91.9K
- CDXS 1.0M
- Earning Date
- DSGN 05-07-2025
- CDXS 05-14-2025
- Dividend Yield
- DSGN N/A
- CDXS N/A
- EPS Growth
- DSGN N/A
- CDXS N/A
- EPS
- DSGN N/A
- CDXS N/A
- Revenue
- DSGN N/A
- CDXS $49,815,000.00
- Revenue This Year
- DSGN N/A
- CDXS $2.41
- Revenue Next Year
- DSGN N/A
- CDXS $34.28
- P/E Ratio
- DSGN N/A
- CDXS N/A
- Revenue Growth
- DSGN N/A
- CDXS N/A
- 52 Week Low
- DSGN $2.60
- CDXS $1.90
- 52 Week High
- DSGN $7.77
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- DSGN 53.86
- CDXS 44.41
- Support Level
- DSGN $3.67
- CDXS $2.25
- Resistance Level
- DSGN $4.13
- CDXS $2.56
- Average True Range (ATR)
- DSGN 0.30
- CDXS 0.20
- MACD
- DSGN 0.05
- CDXS -0.01
- Stochastic Oscillator
- DSGN 85.78
- CDXS 46.62
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.